Does use of aprotinin in coronary artery bypass graft surgery affect graft patency?

Interactive Cardiovascular and Thoracic Surgery

Volumn 3, Issue 1, 2004, Pages 124-128

  Kalkat, Maninder ^a   Levine, Adrian ^a   Dunning, Joel ^b  

^a UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Aprotinin; Evidence based medicine; Graft patency; Meta analysis; Thoracic surgery

Indexed keywords

APROTININ;

ANESTHESIA INDUCTION; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DRUG SAFETY; DRUG USE; GRAFT OCCLUSION; GRAFT PATENCY; HEART SURGERY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REOPERATION; RISK BENEFIT ANALYSIS; SAPHENOUS VEIN GRAFT; THROMBOSIS;

EID: 1842736393     PISSN: 15699293     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1569-9293(03)00234-2     Document Type: Article

References (11)

1. Dunning J, Prendergast B, Mackway-Jones K. Towards evidence-based medicine in cardiothoracic surgery: best BETS. Interactive J Cardiovasc Thorac Surg 2003; Available online 15 September 2003: www.icvts.org/pdf/icvts205.pdf.
2. Henry DA, Moxey AJ, Carless PA, O'Connell D, McClelland B, Henderson KM, Sly K, Laupacis A, Fergusson D. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database of Systematic Reviews 2003.
3. Alderman E.L., Levy J.H., Rich J.B., Nili M., Vidne B., Schaff H., Uretzky G., Pettersson G., Thiis J.J., Hantler C.B., Chaitman B., Nadel A. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial [comment]. J Thorac Cardiovasc Surg. 116:1998;716-730.
4. Havel M., Grabenwoger F., Schneider J., Laufer G., Wollenek G., Owen A., Simon P., Teufelsbauer H., Wolner E. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood [comment]. J Thorac Cardiovasc Surg. 107:1994;807-810.
5. Lemmer J.H. Jr, Stanford W., Bonney S.L., Breen J.F., Chomka E.V., Eldredge W.J., Holt W.W., Karp R.B., Laub G.W., Lipton M.J. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg. 107:1994;543-551.
6. Lass M., Welz A., Kochs M., Mayer G., Schwandt M., Hannekum A. Aprotinin in elective primary bypass surgery. Graft patency and clinical efficacy. Eur J Cardio-Thorac Surg. 9:1995;206-210.
7. Kalangos A., Tayyareci G., Pretre R., Di Dio P., Sezerman O. Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization. Eur J Cardio-Thorac Surg. 8:1994;651-656.
8. Bidstrup B.P., Underwood S.R., Sapsford R.N., Streets E.M. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg. 105:1993;147-152.
9. van der MJ, Hillege HL, Ascoop CA, Dunselman PH, Mulder BJ, van Ommen GV, Pfisterer M, van Gilst WH, Lie KI. Aprotinin in aortocoronary bypass surgery: increased risk of vein-graft occlusion and myocardial infarction? Supportive evidence from a retrospective study. Thromb Haemost 1996;75:1-3.
10. Laub G.W., Riebman J.B., Chen C., Adkins M.S., Anderson W.A., Fernandez J., McGrath L.B. The impact of aprotinin on coronary artery bypass graft patency. Chest. 106:1994;1370-1375.
11. Jegaden O., Vedrinne C., Rossi R. Aprotinin does not compromise arterial graft patency in coronary bypass operations. J Thorac Cardiovasc Surg. 106:1993;180-181.